You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
千紅製藥(002550.SZ)2019年淨利18.62%至2.63億元 擬10派2.5元
格隆匯 04-25 01:50

格隆匯4月25日丨千紅製藥(002550.SZ)披露2019年年度報告,實現營業收入16.75億元,同比增長26.74%;歸屬於上市公司股東的淨利潤2.63億元,同比增長18.62%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.95億元,同比增長80.26%;基本每股收益0.21元。擬向全體股東每10股派發現金紅利2.5元(含税)。

原料藥市場方面,公司在錯綜複雜的原料藥市場行情中,認真梳理客户結構與需求,積極把握市場行情與機遇,2019年原料藥事業部銷售收入同比增長20.44%,繼續穩居國內肝素原料行業前列,同時積極開拓其他高附加值新品種的國際市場,出口產品結構持續優化。

國內製劑銷售市場,公司加強頂層設計,繼續深入實施多元化的銷售模式,自營團隊、代理模式、商業零售、OTC銷售齊頭並進,銷售規模逐年攀升,2019年實現國內製劑銷售收入同比增長32.19%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account